GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Linezolid

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Nebraska Medicine: Linezolid

Product / population
CRRT/PIRRT statement only; select the indication-specific baseline dose separately.
Renal method
Not specified
Source revision
Not established
Retrieved
2026-09-05
Local review status
Source-read local summary; source-specific recommendations are not automatically interchangeable.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Label guidance versus selected expert dose reduction

The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.

What to reconcile: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Linezolid: qualified expert reduction versus label no-adjustment

UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.

What to reconcile: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

Nebraska Medicine: Linezolid

Open original reference

UNMC / Nebraska Medicine · CRRT/PIRRT statement only; select the indication-specific baseline dose separately.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Renal-replacement statement

Linezolid is listed among agents not requiring adjustment specifically for CRRT/PIRRT.

linezolid:unmc-crrt-statement-linezolid-1 · Source locator: PDF page 2: no-adjustment list

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf
Retrieved
2026-09-05
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
73d43752d92d45630cac28d8b32244561938e0cf51efe7fb84ee1f0454dbe482

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=linezolid&s1=unmc-crrt-statement-linezolid&h1=f5c929f116ebf47133f6ddc0c2d07c94138eb9ac788d3d4c64001a0fde83cc42